ArticleCells2026
The Making of Synaptic Ribbons: Carboxy-Terminal Tagging of RIBEYE B-Domain Reduces Steady-State Levels of RIBEYE and Its Efficacy to Build Synaptic Ribbons.
Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
RIBEYE is the central building block of synaptic ribbons, the eponymous presynaptic specializations of ribbon synapses. RIBEYE consists of two major protein regions: a unique amino-terminal, proline-rich A-domain and a carboxy-terminal, NADH-binding B-domain, which is largely identical to tetramer-forming nuclear protein CtBP2. In RIBEYE knockout mice, synaptic ribbons are completely absent, emphasizing the central role of RIBEYE in making synaptic ribbons. In the present study, we used a previously generated transgenic RIBEYE mouse line, in which a large protein tag was fused to the carboxy-terminus of RIBEYE-B-domain (RIBEYE-C-TG). We generated RIBEYE-C-TG-expressing RIBEYE knockout mice to study the impact of carboxy-terminal tagging of RIBEYE B-domain on synaptic ribbon formation. We applied high-resolution confocal immunofluorescence microscopy, conventional and E-PTA transmission electron microscopy to analyze whether carboxy-terminally tagged RIBEYE-C-TG rescues synaptic ribbon deficiency in RIBEYE knockout mice and restores synaptic ribbon in situ. High-resolution immunofluorescence microscopy revealed that transgenic RIBEYE-C-TG expression rescued synaptic ribbon formation in RIBEYE knockout mice. Electron microscopy confirmed that transgenic ribbons consisting of transgenic RIBEYE-C-TG were made, anchored to the active zone, and associated with synaptic vesicles. But transgenic synaptic ribbons formed by RIBEYE-C-TG were considerably smaller in size than synaptic ribbons in control mice. The expression level of RIBEYE-C-TG protein was much lower than untagged RIBEYE protein as demonstrated by qualitative and quantitative Western blot analyses. The decreased expression level of RIBEYE-C-TG protein is not due to decreased activity of the transgenic RIBEYE promoter or alterations of the 5'-UTR as shown by RT-qPCR analyses of RIBEYE transcripts and reporter assays. Our findings suggest that carboxy-terminally tagged RIBEYE-C-TG protein is less stable and less efficient in making synaptic ribbons than the untagged RIBEYE protein. Based on the findings in this study and on recently published structural data from other groups on RIBEYE and RIBEYE B-domain/CtBP2, we predict that carboxy-terminal tagging of RIBEYE B-domain, placed at the interaction interface of RIBEYE B-domain tetramers/RIBEYE B-domain filaments, could interfere with the formation and/or stability of RIBEYE B-domain-dependent oligomeric complexes which are likely essential to build the synaptic ribbon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.